ストックスクリーナーアプリを入手
7.57
5.85%
-0.47
前日終値:
$8.04
開ける：
$8.04
24時間の取引高:
260.78K
Relative Volume:
1.09
時価総額：
$408.22M
収益：
当期純損益:
$-35.10M
株価収益率:
-10.74
EPS:
-0.7051
ネットキャッシュフロー:
$-31.49M
1週間 パフォーマンス:
-9.12%
1か月 パフォーマンス:
+14.18%
6か月 パフォーマンス:
+14.35%
1年 パフォーマンス:
+13.32%
1日の値動き範囲:
$7.53
$8.10
1週間の範囲:
$7.53
$8.335
52週間の値動き範囲:
$5.245
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
名前
Diamedica Therapeutics Inc
セクター
電話
(763) 496-5454
住所
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
7.57 | 408.22M | 0 | -35.10M | -31.49M | -0.7051 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-14 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-10-30 | 開始されました | TD Cowen | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-06-22 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-04-09 | 開始されました | Oppenheimer | Outperform |
| 2021-02-17 | 開始されました | ROTH Capital | Buy |
| 2020-10-30 | 開始されました | Guggenheim | Buy |
| 2020-07-08 | 開始されました | Maxim Group | Buy |
| 2019-04-30 | 開始されました | Dougherty & Company | Buy |
| 2019-03-05 | 開始されました | Lake Street | Buy |
すべてを表示
Diamedica Therapeutics Inc (DMAC) 最新ニュース
Price to earnings forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
(DMAC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
DiaMedica Therapeutics Inc. (DMAC) Key Financial Ratios – Valuation, Profitability & More - Value Research
DiaMedica Therapeutics Inc. (DMAC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Four New York investor talks are planned for September by DiaMedica - Stock Titan
Zomedica Corp. (ZOM) Peer Comparison – Compare with Others - Value Research
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
Understanding the Setup: (DMAC) and Scalable Risk - Stock Traders Daily
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Yahoo Finance
DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
DiaMedica (DMAC) Results Versus Estimates: EPS Lands Above Forecast; Share Response: The Market Price Advances 1.82% in the Current UpdateManagement Tone Analysis - vinanet.vn
DiaMedica's DM199: Multiple Catalysts AheadWill It Deliver? - RTTNews
META_TITLE_QUOTE - Yahoo Finance
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - AOL.com
DMAC Q2 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined SpendingEBITDA Estimate Trend - Vinanet
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - The Globe and Mail
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceBPI Bear Correction - vinanet.vn
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceGap and Reverse - siam.in
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeWatchlist Stock Ideas - vinanet.vn
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeVWAP Deviation - dars.gov.et
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - MarketBeat
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - The Globe and Mail
DiaMedica Therapeutics CEO John Dietrich Pauls Awarded 60,200 Restricted Stock Units on August 10, 2026 - Kalkine Media
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - TipRanks
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - TipRanks
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - TradingView
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
H.C. Wainwright Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $12 - Moomoo
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - MarketBeat
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and ResistanceSymmetrical Triangle - vinanet.vn
Diamedica Therapeutics Inc (DMAC) 財務データ
収益
当期純利益
現金流量
EPS
Diamedica Therapeutics Inc (DMAC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| STAHLBERG JAN | 10% Owner |
Nov 25 '25 |
Buy |
8.57 |
73,099 |
626,817 |
8,825,742 |
| STAHLBERG JAN | 10% Owner |
Nov 24 '25 |
Buy |
7.89 |
40,253 |
317,721 |
8,752,643 |
| Parsons James T. | Director |
Nov 21 '25 |
Option Exercise |
2.20 |
12,000 |
26,400 |
87,854 |
| STAHLBERG JAN | 10% Owner |
Nov 21 '25 |
Buy |
7.41 |
208,872 |
1,547,574 |
8,712,390 |
| STAHLBERG JAN | 10% Owner |
Nov 20 '25 |
Buy |
7.41 |
128,426 |
951,213 |
8,503,518 |
| STAHLBERG JAN | 10% Owner |
Nov 18 '25 |
Buy |
6.75 |
182,882 |
1,234,618 |
8,134,740 |
| STAHLBERG JAN | 10% Owner |
Nov 17 '25 |
Buy |
6.52 |
187,393 |
1,221,165 |
7,951,858 |
4.22%
大文字化:
|
ボリューム (24 時間):